gvtcx

NHS National Framework for Natalizumab-February 2024

NHS England Published 2 Feb 2024 Contracts Finder
The value below is a framework or dynamic market ceiling: the maximum that could be spent across all call-offs, not the value of a single contract. Aggregate figures on this site exclude these to avoid double counting.

key details

Value£175,000,000
Statuscomplete
Category (CPV) 33600000
Deadline4 Dec 2023
Procedureopen
OCIDocds-h6vhtk-041149

Awards (5)

This procurement was awarded to 5 suppliers. Values shown are per-award; the notice total is £175,000,000.

SupplierValueDateStatus
Alexion Pharmaceuticals shared · · active
Amgen Ltd shared · · active
Biogen shared · · active
Samsung Bioepis UK Ltd shared · · active
Sandoz Ltd shared · · active

description

NHS National Framework for Natalizumab - February 2024<br/>Offer reference number: CM/PHR/23/5701<br/>Period of framework: 1 February 2024 to 31 August 2025 with an option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months

documents

Documents are linked, not mirrored. They are served by the publishing authority and may require registration.

notice history

5 notices published against this procurement.

PublishedTypeRegimeNotice
26 Oct 2023 Contract notice (F02) Earlier regulations 031590-2023
2 Nov 2023 Contract notice (F02) Earlier regulations 032448-2023
2 Nov 2023 Tender (tender) · f649dcd3-2781-4038-a770-a8f09c6db70d-694429
2 Feb 2024 Contract award notice (F03) Earlier regulations 003529-2024
2 Feb 2024 Contract award notice (F03) Earlier regulations 003528-2024

more from NHS England

all contracts from this buyer →

similar contracts awarded

Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.

source

Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.